Fate Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $1,907 | $1,629 | $1,860 | $3,074 |
Gross Profit | -1,371 | 1,629 | 1,860 | 3,074 |
EBITDA | -36,968 | -37,947 | -42,198 | -47,770 |
EBIT | -40,246 | -41,280 | -47,011 | -52,377 |
Net Income | -34,070 | -37,621 | -52,153 | -47,678 |
Net Change In Cash | 1,907 | 1,629 | 1,860 | 3,074 |
Free Cash Flow | -25,949 | -35,005 | -27,897 | -29,914 |
Cash | 41,249 | 44,920 | 36,056 | 37,909 |
Basic Shares | 118,528 | 118,375 | 117,794 | 117,769 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $13,631 | $63,533 | $96,300 | $55,846 |
Gross Profit | 13,631 | -93,654 | 96,300 | 49,996 |
EBITDA | -176,577 | -172,229 | -294,628 | -211,144 |
EBIT | -195,539 | -190,511 | -308,386 | -216,994 |
Net Income | -186,262 | -160,928 | -255,056 | -212,151 |
Net Change In Cash | 13,631 | 63,533 | 96,300 | 55,846 |
Cost of Revenue | -33,764 | |||
Free Cash Flow | -123,604 | -138,416 | -283,774 | -213,574 |
Cash | 36,056 | 41,870 | 61,333 | 133,583 |
Basic Shares | 113,685 | 98,411 | 96,826 | 94,747 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.29 |
2025-03-31 | -$0.32 |
2024-12-31 | -$0.44 |
